DRUG DEVELOPMENT
 
 The drug discovery and development process follows a systematic and thoroughly planned strategy KINAPTEX (according to the Greek term anaptuxh for growth and development).  

KINAPTEX relies on a powerful combination of experimental protein-drug structure determination, computational modeling, and validation procedures accelerating the development of new and optimized chemical compounds with therapeutic potential. 

Thus, the KINARIS team has identified and characterized several bioactive compounds from different chemical classes that specifically target myosin isoforms and myosin classes by a structurally and functionally well characterized mechanism of allosteric modulation.

 KINAPTEX


 

Structure Determination and in silico Modeling   High-Throughput Functional Assays.
 
  • Powerful protein structure determination and in silico technologies are at the heart of the multi-stage drug development process KINAPTEX.
     

  • High performance X-ray crystallography allows fast structure determination of the target protein/lead compound complexes. The 3D-structures form the basis for the efficient optimization of the drug candidates towards the development of highly efficient and specific myosin inhibitors and myosin activators.
     

  • Computational methods assist the drug development process by virtual screening using docking procedures and extracting physico-chemical properties from modeling.
   
  • We introduce further efficiencies to drug discovery by performing functional assays and using approved model organisms to elucidate the mode of drug/target protein interaction, confirm selectivity, and test for bioavailability in order to obtain the most potent drug candidates.

 
   

IMPRINT  |  CONTACT  |  DISCLAIMER